News & Events

Blog

  • March 29, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken, RPh, MS; Contributor, Meghan Mosser

    Disruption is coming to the healthcare industry.  In recent months multiple announcements have been made about enterprises joining together. Between Amazon dabbling in the pharmacy industry and CVS and Aetna announcing a potential merger, disruption is here. But it doesn’t stop there. Now Amazon, Berkshire Hathaway and JPMorgan have a plan to overhaul health insurance.  […]

  • March 14, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken, RPH, MS; Contributor: Meghan Mosser

    Several articles have been published about CVS buying the insurance company Aetna, including the Wall Street Journal.  The article claimed there was a hidden reason behind this venture. That hidden reason was summed up in one word:  Amazon.  In my opinion, this is correct. Two major healthcare companies are joining forces to likely compete against […]

  • March 7, 2017
    Posted by: Theresa Matkovits, Ph.D., Senior Vice President, Head of Drug Development, ContraVir Pharmaceuticals

    The high failure rate of clinical trials has significant impact on providing potential curative treatments to patients in need. It is with this goal in mind that innovators struggle in designing clinical programs that can bring life-changing treatments to market. Drug development remains a high cost and risky undertaking, given the high failure rate if […]

  • February 28, 2017
    Posted by: Nicki Norris, Chief Executive Officer, Symphony Clinical Research

    In the US, pharmaceutical and biotechnology companies sponsor the majority (75%) of clinical trials. In total, these companies spent approximately $40 billion on clinical research in 2014. [1] Clinical trials such as these are the first point of interaction between a patient and a sponsor company. In spite of this, clinical teams frequently overlook this […]

  • February 21, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is the third and last part of a 3-part series on strategic considerations for patient engagement, market access and promotion for medical devices and procedures. In this blog, we’ll discuss the important factors from the Company’s perspective. We’ll look to discuss what the mission critical factors are for device success, after you’ve completed all […]

  • February 7, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is the second part of a 3-part series on strategic considerations for patient engagement, market access and promotion for medical devices and procedures. In this blog, we’ll discuss the important factors from the payer’s perspective that many times are overlooked and not given their full due by well-meaning corporate teams. As an early disclaimer, […]

  • January 31, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is the first part of a 3-part series on strategic considerations for patient engagement, market access and promotion for medical devices and procedures. We will discuss what many times gets overlooked, de-prioritized, or lost in the gaps by well-meaning corporate teams. The end first – “If you do not change direction, you may end […]

  • January 24, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    The confetti has cleared the air, the champagne bottle is empty and the sun is shining on the day after your device has gained FDA clearance. You want to believe the hard-part is over and from here on it is smooth sailing into the sunset, with an umbrella drink in hand, and payers in line […]

  • January 17, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    We’ve all been there before if you’ve been doing clinical trials for some time: the protocol is approved, patients are recruited and enrolled, clinical sites engage and monitor their patients and then the happy day of the last patient visit. However, don’t pop the bubbly just yet because the database needs to be locked and […]

  • January 10, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    Clinical trials are more complex, more involved and span the globe. Clinical trials involve people, patients, stakeholders, researchers, administrators, and regulators, to name just a few. Next: add on training, monitoring and oversight to provide quality data in a short time-frame and you have a recipe for disaster! What’s a poor boy (or girl) to […]

  • Case Study
    A Biopharmaceutical Company Sponsoring a Phase III Clinical Trial in the U.S.
    read more...
  • Latest News
    Center Point Clinical Services Names Gerald E. Finken New CEO
    March 15, 2018
    read more...
  • Need More Information?